How Quickly Do Steroids Cause Cataracts?

Steroid-induced cataracts can begin forming in as little as a few months of regular use, though most people on moderate doses will not notice visual changes for a year or longer. The speed depends heavily on the dose, the route of delivery, and individual susceptibility. In laboratory lens models, detectable opacities appear within 48 hours of glucocorticoid exposure, but real-world clinical timelines are more nuanced and variable than that dramatic figure suggests.

The Type of Cataract Steroids Produce

Steroids do not cause just any clouding of the lens. They produce a specific pattern called a posterior subcapsular cataract, or PSC. This opacity forms at the very back of the lens, right along the visual axis, which is why even a small steroid cataract can cause disproportionate glare and difficulty reading compared to other cataract types of similar size. PSCs have three distinguishing features: they are linked only to steroids with glucocorticoid activity, they involve abnormal migration of lens cells to the wrong location, and they consistently appear in that central rear position.¹ The connection between steroids and this particular cataract type was first documented in 1960, when researchers noticed that 39% of rheumatoid arthritis patients on long-term corticosteroids had developed PSCs, while those not on steroids had none.²

Oral and Systemic Steroids Have the Fastest Clinical Timeline

When you take steroids by mouth or receive them intravenously, the drug reaches every tissue, including the lens. This systemic exposure is where the highest cataract risk lives, and where cataracts develop most quickly. In children with autoimmune diseases treated with oral glucocorticoids, posterior subcapsular cataracts started appearing at the six-month mark in about 18% of patients. By twelve months the rate had risen to roughly 35%, and by eighteen months it reached about 41%.³ That progression from zero to substantial risk within a year and a half is a pattern clinicians watch for closely in anyone on chronic oral steroids.

Adults on high-dose regimens can develop cataracts even faster. Patients with multiple myeloma receiving dexamethasone-based chemotherapy showed a 36% cataract rate within just six treatment cycles, with higher cumulative dexamethasone doses correlating directly with worse lens changes.⁴ Dexamethasone is far more potent than prednisone, which helps explain the speed. Among people with lupus, a cumulative prednisone exposure equivalent to 10 mg per day for ten years was a strong predictor of cataract, roughly tripling the risk.⁵ That ten-year figure might sound reassuring, but it represents a relatively modest daily dose. People on higher doses accumulate the same total exposure much sooner.

The takeaway for systemic steroids is that measurable lens changes can start within months on moderate-to-high doses. Noticeable visual symptoms usually lag behind, because a PSC has to grow large enough to interfere with light before you feel it. Someone might have early lens opacities on a slit-lamp exam well before they notice blurry reading vision or glare from headlights at night.

Inhaled Steroids Carry a Real but Smaller Risk

Millions of people use inhaled corticosteroids daily for asthma or COPD, so the cataract question matters enormously for this group. The risk is real, but it is much lower than with oral steroids because far less drug reaches the bloodstream. A large meta-analysis found that high-dose inhaled steroids (at or above 1,000 micrograms per day of beclomethasone equivalent) significantly increase cataract risk and the likelihood of eventually needing cataract surgery.⁶

The dose-response relationship is clear. One large study found that each additional 1,000 micrograms per day of inhaled beclomethasone (or its equivalent) raised cataract risk by about 19%. Even at daily doses under 500 micrograms, there was a small but statistically detectable increase in risk of about 11%.⁷ For people on the highest doses, the risk climbed to about 44% above baseline. A population-based study similarly found that the association between inhaled steroids and cataracts strengthened with both higher daily doses and longer duration of use, with adjusted odds ratios rising from essentially no increase at doses under 400 micrograms to about 1.7 for doses above 1,600 micrograms.⁸

Among COPD patients specifically, high-dose inhaled steroids (above 500 micrograms per day of fluticasone equivalents) produced a cataract prevalence of roughly 40% after more than twelve months of exposure, while low-dose users showed no meaningful increase.⁴ The practical implication is that if your inhaler dose is on the lower end and well-controlled, the added cataract risk is small. If you have been on high-dose inhaled steroids for years, the risk becomes substantial enough to warrant regular eye exams.

One study of lifetime cumulative inhaled beclomethasone use found that among people whose total lifetime dose exceeded 2,000 milligrams, 27% had posterior subcapsular cataracts, a prevalence more than five times higher than in non-users.⁹ That cumulative figure takes years to reach, which is why inhaled steroid cataracts tend to develop over a longer timescale than those from oral use.

Steroid Eye Drops and Injections Deliver the Drug Straight to the Lens

When steroids are delivered directly into or around the eye, the lens gets a concentrated local dose, which can accelerate cataract formation compared to what you would see from the same drug taken orally. Intravitreal triamcinolone injections, commonly used for macular edema and retinal inflammation, illustrate this well. In a study comparing injected eyes to untreated fellow eyes, a single injection produced measurably more posterior subcapsular cataract progression than no injection, and multiple injections made the difference even larger. Among the study eyes, eleven eventually needed cataract surgery during follow-up, compared to just two control eyes.¹⁰ Cataract progression correlated with both the number of injections and the length of follow-up, so repeated injections compress the timeline.

There is an interesting wrinkle with intravitreal steroids: eyes that develop elevated eye pressure after the injection are at much higher risk of rapid PSC formation than eyes whose pressure stays normal. Researchers have suggested that the mechanisms behind steroid-induced raised pressure and steroid-induced cataracts may overlap.¹¹ If your ophthalmologist gives you a steroid injection and your eye pressure climbs afterward, the chances of a fast-developing cataract in that eye go up substantially.

Steroid eye drops used long-term, such as for chronic uveitis or after eye surgery, also carry meaningful cataract risk. The exact speed depends on the strength and frequency of the drops, but because the drug is applied directly to the eye surface, significant amounts penetrate to the lens. Short courses of a few weeks carry minimal risk, but months of daily steroid eye drops put you in the zone where lens changes can start.

Nasal Sprays Are Largely in the Clear

If you use a steroid nasal spray for allergies, the cataract news is reassuring. A systematic review and meta-analysis found that the increased incidence of posterior subcapsular cataracts in people using intranasal corticosteroids versus placebo was just 0.02%, which was not statistically significant.¹² A separate population-based study found that the cataract rate among intranasal steroid users was about 1 per 1,000 person-years, the same as in non-users, with no increase related to the number of prescriptions filled.¹³ The systemic absorption from nasal sprays is low enough that the lens essentially never sees a clinically relevant dose. This is worth knowing, because people sometimes lump all steroid formulations together when worrying about side effects.

Why Glucocorticoids Specifically Damage the Lens

Not all steroids cause cataracts. Anabolic steroids, sex hormones, and mineralocorticoids do not produce this effect. Only steroids with glucocorticoid activity do, which points to a mechanism tied specifically to how glucocorticoids interact with receptors in lens cells. Research has shown that glucocorticoids deplete the lens of reduced glutathione, an antioxidant that normally protects lens proteins from oxidative damage. In animal models, this glutathione depletion happens quickly: the liver loses about half its glutathione within 24 hours, lipid peroxides spike dramatically, and detectable lens opacities follow within 48 hours.⁴

Early research suspected that steroids might cause cataracts by physically binding to lens proteins and altering their structure, but that theory has largely fallen apart. Studies showed that non-glucocorticoid steroids bind lens proteins just as well or better than glucocorticoids, yet they do not produce cataracts. What distinguishes glucocorticoids is their ability to lower lens glutathione, which connects steroid cataracts to the same oxidative stress pathway seen in other forms of cataract.¹⁴ When glucocorticoid receptors are activated in lens cells, they trigger changes in gene activity that promote cell proliferation, reduce normal cell death, and increase reactive oxygen species, all of which contribute to the abnormal cell migration that defines a PSC.¹

Children Can Develop Steroid Cataracts Faster

Children appear to be particularly susceptible to steroid-induced cataracts, and the timeline can be compressed. In pediatric patients with nephrotic syndrome receiving long-term oral corticosteroids, about 18% developed cataracts, with higher cumulative doses and longer treatment durations (an average of about four years versus two years in unaffected children) driving the risk.⁴ In children with autoimmune diseases, the progression from first detectable PSC at six months to more than 40% affected at eighteen months is notably steep.³

There is some good news in the long-term pediatric data, though. In a study following 59 eyes of 30 children with steroid-induced PSCs over an average of about seven and a half years, cataracts progressed in 34% of eyes but remained stable in the other 66%. Only three children ultimately needed cataract surgery. For the 90% who avoided surgery, visual acuity did not significantly decline during the follow-up period.¹⁵ This suggests that once steroids are reduced or stopped, many early cataracts in children stabilize rather than marching inexorably toward surgery.

Can Steroid Cataracts Reverse?

A common question is whether stopping steroids will make the cataract go away. Established lens opacities, once formed, generally do not reverse. The protein changes and abnormal cell deposits that make up a PSC are structural; stopping the drug does not undo them. What can happen, as the pediatric data above shows, is that early cataracts may stop progressing once the steroid is withdrawn or the dose is significantly reduced. Whether a given cataract stabilizes or worsens seems to depend on how advanced it was when the steroid dose dropped, whether the patient continues any steroid exposure from other routes, and individual factors that are not yet well understood.

For many people, small steroid-induced PSCs remain too minor to affect daily vision. The cataract is there on the slit-lamp exam, but the person reads comfortably and drives without trouble. In those cases, monitoring alone is reasonable. When the cataract does progress to the point where vision is impaired, standard cataract surgery (replacing the clouded lens with an artificial one) works just as well as it does for age-related cataracts. The surgery itself is no more complicated because the cataract was steroid-induced.

Reducing Your Risk While Still Taking Steroids

For many patients, steroids are not optional. The conditions they treat, including severe asthma, organ transplant rejection, autoimmune diseases, and inflammatory eye conditions, can be sight-threatening or life-threatening without them. The practical question is how to minimize cataract risk without sacrificing disease control.

The most effective strategy is to use the lowest dose for the shortest time possible. Current guidelines for inflammatory conditions like uveitis recommend starting steroid-sparing therapy if systemic corticosteroids cannot be tapered below 7.5 mg of prednisone within three months.¹⁶ In practice, some patients remain on steroids longer than they need to because the transition to alternative drugs is slow. That delay adds cumulative dose and increases cataract risk.

Other practical steps include choosing the least systemically absorbed route when possible (inhaled over oral, nasal spray over inhaled for upper-airway allergy symptoms), rinsing your mouth after using an inhaler to reduce the small amount that gets swallowed, and scheduling regular slit-lamp eye exams to catch early lens changes before they affect vision. The frequency of eye checks should scale with your steroid dose and duration: someone on a short burst for a flare needs less monitoring than someone on chronic daily prednisone.

Why Individual Variation Is So Wide

One of the frustrating realities of steroid cataracts is that some people develop them quickly on moderate doses while others take high doses for years without significant lens changes. The 1960 rheumatoid arthritis study found that 39% of patients on long-term steroids had PSCs, which also means 61% did not.² More than sixty years later, we still cannot reliably predict who falls in which group before treatment starts.

Some of this variability likely comes down to differences in glucocorticoid receptor sensitivity, antioxidant capacity within the lens, and how efficiently individuals metabolize steroid drugs. Age matters, with children and older adults appearing more susceptible. Diabetes is another known risk factor for cataracts in general, and adding steroids (which also raise blood sugar) likely compounds the risk, though parsing the steroid contribution from the diabetes contribution is difficult. The presence of elevated eye pressure after steroid exposure, as seen in the intravitreal injection studies, may also serve as a marker for people whose eyes are more sensitive to steroids across the board.¹¹

Steroid Potency and How It Affects the Clock

Not all corticosteroids are created equal. Dexamethasone is roughly six to seven times more potent than prednisone milligram for milligram, and the cataract data reflects this. The 36% cataract rate within six treatment cycles in myeloma patients on dexamethasone is strikingly fast compared to the timelines seen with prednisone, where meaningful risk typically accumulates over a year or more.⁴ Among inhaled steroids, the specific molecule also matters. Fluticasone, budesonide, and beclomethasone have different systemic absorption profiles and different potencies, which partly explains why studies comparing them sometimes reach slightly different cataract risk estimates. The dose conversion matters: 500 micrograms of fluticasone delivers roughly the same glucocorticoid punch as 1,000 micrograms of beclomethasone.

For anyone trying to gauge their personal risk, the relevant number is not just the daily dose but the cumulative lifetime exposure expressed in a common equivalent. A person who took 20 mg of prednisone daily for six months has a very different cumulative exposure than someone who took 5 mg daily for five years, even though the latter’s total is higher. Both dose intensity and duration independently contribute to lens damage, and the dose-response curves from the large studies make clear that there is no clean threshold below which the risk is zero. It starts small and climbs steadily.

1
PubMed. The etiology of steroid cataract
2
JAMA. Posterior Subcapsular Cataracts Induced by Corticosteroids in Patients with Rheumatoid Arthritis
3
PubMed. The occurrence timeline of steroid-induced ocular hypertension and cataract in children with systemic autoimmune diseases
4
PubMed Central. Cataract Induced by Glucocorticoids
5
ACR Meeting Abstracts. Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)
6
PubMed Central. Inhaled Corticosteroid Exposure and Risk of Cataract in Patients with Asthma and COPD: A Systematic Review and Meta-Analysis
7
European Respiratory Journal. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
8
PubMed Central. A population based case-control study of cataract and inhaled corticosteroids
9
PubMed. Use of inhaled corticosteroids and the risk of cataracts
10
PubMed. Cataract progression after intravitreal triamcinolone injection
11
Ophthalmology. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract
12
PubMed Central. Intranasal corticosteroids do not lead to ocular changes: a systematic review and meta-analysis
13
PubMed. Risk of cataract among users of intranasal corticosteroids
14
PubMed. Steroid-induced cataract: new perspective from in vitro and lens culture studies
15
PubMed. Systemic steroid-induced cataracts in children: long-term changes in morphology and visual acuity
16
Eye. Timing of corticosteroid-sparing therapies in non-infectious uveitis: a population-based cohort study from Denmark